Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30026002

Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Aug
First author
Friedlander M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Oct;19(10):e504. doi: 10.1016/S1470-2045(18)30623-5.
    note
    Source null
    related pmid
    30303117
    relationship
    Comment in

Authors and identifiers

  1. name
    Friedlander M
    type
    Author
  2. name
    Gebski V
    type
    Author
  3. name
    Gibbs E
    type
    Author
  4. name
    Davies L
    type
    Author
  5. name
    Bloomfield R
    type
    Author
  6. name
    Hilpert F
    type
    Author
  7. name
    Wenzel LB
    type
    Author
  8. name
    Eek D
    type
    Author
  9. name
    Rodrigues M
    type
    Author
  10. name
    Clamp A
    type
    Author
  11. name
    Penson RT
    type
    Author
  12. name
    Provencher D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Friedlander M
    type
    Author
  2. name
    Gebski V
    type
    Author
  3. name
    Gibbs E
    type
    Author
  4. name
    Davies L
    type
    Author
  5. name
    Bloomfield R
    type
    Author
  6. name
    Hilpert F
    type
    Author
  7. name
    Wenzel LB
    type
    Author
  8. name
    Eek D
    type
    Author
  9. name
    Rodrigues M
    type
    Author
  10. name
    Clamp A
    type
    Author
  11. name
    Penson RT
    type
    Author
  12. name
    Provencher D
    type
    Author
bibliography ids
  1. nci-bib-0c5e82a93342a926d93a4941
book metadata
content sha256
59bec0774adb6f194ff4700471905dc9ba6853d79ada2440358795806652580c
document type
citation
dois
  1. 10.1016/S1470-2045(18)30343-7
electronic publication date
display
2018 Jul 17
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30026002
immutable id
pubmed:30026002@59bec0774adb6f194ff4700471905dc9ba6853d79ada2440358795806652580c
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
1126-1134
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Oct;19(10):e504. doi: 10.1016/S1470-2045(18)30623-5.
    note
    Source null
    related pmid
    30303117
    relationship
    Comment in
outcomes validated
false
pmid
30026002
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
36e0fe99a5255cadd7a88caed0450c3c7f50ef675a335b2aca9699c8558b780c
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Aug
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30026002/
title
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

Preserved source evidence · Not medical advice